Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT)

Oleg Shukhov, Margarita Gurianova, Ekaterina Chelysheva, Anna Petrova, Anastasiya Bykova, Irina Nemchenko, Andrey Sudarikov, Elena Kuzmina, Lyubov Gavrilova, Alina Kokhno, Anna Turkina

Blood (2024) 144 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2024-199962

Published: 2024

Journal Articles

The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia

Elena Kuzmina, Ekaterina Chelysheva, Elza Lomaia, Elena V Morozova, Oleg Shukhov, Anna Petrova, Tamara Chitanava, Julia Vlasova, Evgenia Sbitiakova, Natalia Lazorko, Irina Nemchenko, Anastasiya Vitalievna Bykova, Margarita Gurianova, Alina Kokhno, Anna Turkina

Blood (2023) 142 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2023-181789

Published: 2023

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Ekaterina Chelysheva, MD PhD, Jane Apperley, MB ChB MD, Elisabetta Abruzzese, Dong-Wook Kim, MD PhD, Konstantin Kotlyarchuk, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2018-99-115984

Published: 2018

Journal Articles

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Anna Petrova, MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G Turkina, Prof., MD, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Ionova, DSc

Blood (2018) 132 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2018-99-113360

Published: 2018

Journal Articles

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Galina Gusarova, MD PhD, Eduard Gemdzhian, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2018-99-116321

Published: 2018

Journal Articles

Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra -Positive Neoplasm

Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2018-99-116262

Published: 2018

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

Alterations in Mesenchymal Stromal Precursor Cells in Patients with Chronic Myeloid Leukemia at the Onset of the Disease and During Treatment By Tyrosine Kinase Inhibitors

Nataliya Petinati, PhD MD, Irina Shipounova, PhD, Alexey Bigildeev, PhD, Natalia Sats, PhD, Tamara Sorokina, MD, Ekaterina Chelysheva, MDPhD, Oleg Shukhov, MDPhD, Anna Petrova, MD, Anna G Turkina, Prof., MD, Nina Drize, PhD

Blood (2017) 130 (Supplement 1): 5242.

https://doi.org/10.1182/blood.V130.Suppl_1.5242.5242

Published: 2017

Journal Articles

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Mikhail Fominykh, MD, Vasily Shuvaev, MD, Irina Martynkevich, DSc, Oleg Shukhov, MD, Ekaterina Chelysheva, MD, Anna G Turkina, Prof., MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5437.

https://doi.org/10.1182/blood.V128.22.5437.5437

Published: 2016

Journal Articles

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Alexander V Lavrov, MD PhD, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Chelysheva, MD, Oleg Shukhov, MD, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Prof., MD, Sergey Kutsev

Blood (2016) 128 (22): 5457.

https://doi.org/10.1182/blood.V128.22.5457.5457

Published: 2016

Journal Articles

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Blood (2015) 126 (23): 5150.

https://doi.org/10.1182/blood.V126.23.5150.5150

Published: 2015

Journal Articles

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Galina Gusarova, MD PhD, Anastasia Bykova, MD, Alexandra Vorontsova, MD PhD, Sergey Kuznetsov, MD, Oleg Shukhov, MD, Ekaterina Chelysheva, MD PhD, Olga Lazareva, MD PhD, Svetlana Goryacheva, MD PhD, Tatyana Ivanova, MD PhD, Anna G. Turkina, MD PhD

Blood (2015) 126 (23): 5141.

https://doi.org/10.1182/blood.V126.23.5141.5141

Published: 2015

Journal Articles

Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia

Tamara Sorokina, MD, Irina Shipounova, PhD, Alexey Bigildeev, PhD, Nataliya Petinati, PhD, Nina I. Drize, PhD, Anna Turkina, Prof., MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD, Larisa A. Kuzmina, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G Savchenko, PhD MD

Blood (2015) 126 (23): 4768.

https://doi.org/10.1182/blood.V126.23.4768.4768

Published: 2015

Journal Articles

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Blood (2014) 124 (21): 3148.

https://doi.org/10.1182/blood.V124.21.3148.3148

Published: 2014

Journal Articles

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Anna G. Turkina, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Vasiliy Shuvaev, Galina Gusarova, MD PhD, Anastasia Bykova, MD, Olga V. Lazareva, PhD, Oleg Shukhov, MD, Adham Abdullaev, MD PhD, Irina Martynkevich, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5518.

https://doi.org/10.1182/blood.V124.21.5518.5518

Published: 2014

NARROW

Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT)

The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra -Positive Neoplasm

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Alterations in Mesenchymal Stromal Precursor Cells in Patients with Chronic Myeloid Leukemia at the Onset of the Disease and During Treatment By Tyrosine Kinase Inhibitors

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Treatment Cessation in Chronic Myeloid Leukemia As a Part of Treatment Process: Toxicity Determined and Active Stop of Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only